Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Down Syndrome Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991800
Published Content info 377 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Down Syndrome Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 377 Pages
Description

Global Down syndrome market is projected to register a CAGR of 14.2% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

Global Down Syndrome Market, By Disease Type (Trisomy 21, Translocation Down Syndrome, Mosaic Down Syndrome), Treatment (Diagnosis, Therapy), End User (Hospital, Clinics, Homecare Setting, Therapy Centers, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Kuwait, Egypt, Rest of Middle East & Africa) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of global Down syndrome market are:

  • Rising awareness about the disease
  • Increasing government support

Market Players:

The key market players for global Down syndrome market are listed below:

  • Natera, Inc.
  • Next Biosciences
  • AtilaBiosystems
  • Myriad Genetics, Inc.
  • PerkinElmer Inc.
  • F. Hoffmann-La Roche Ltd
  • Demeditec Diagnostics GmbH'
  • Thermo Fisher Scientific Inc.
  • Abnova Corporation
  • Novus Biologicals (a subsidiary of Bio-Techne)
  • Mayo Clinic Health System
  • Boys Town National Research Hospital
  • Boston Children's Hospital
  • Kid Sense Child Development Corporation Pty Ltd
  • Down Syndrome Cork , a branch of Down Syndrome Ireland
  • Children's Hospital Colorado
  • ASDclinic.co.uk, Symbol
  • Abbott
  • Physio.co.uk.
  • Illumina, Inc.
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL DOWN SYNDROME MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TREATMENT OF DOWN SYNDROME LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 MARKET END USER COVERAGE GRID
  • 2.11 VENDOR SHARE ANALYSIS
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 GLOBAL DOWN SYNDROME MARKET: PIPELINE ANALYSIS

  • 4.1 PIPELINE PRODUCTS IMPACT ANALYSIS
  • 4.2 NNI-351
  • 4.3 ASPARAGINASE
  • 4.4 ANVS-401
  • 4.5 QUILLIVANT XR
  • 4.6 TOFACITINIB
  • 4.7 MEMANTINE HYDROCHLORIDE
  • 4.8 NICOTINE
  • 4.9 AEF0217
  • 4.10 ACI-24

5 GLOBAL DOWN SYNDROME MARKET: LAWS AND REGULATIONS

6 MARKET OVERVIEW

  • 6.1 DRIVERS
    • 6.1.1 INCREASING PREVALENCE OF DOWN SYNDROME
    • 6.1.2 RISING DEMAND OF EFFECTIVE THERAPIES
    • 6.1.3 RISING AWARENESS ABOUT THE DISEASE
    • 6.1.4 TECHNOLOGICAL ADVANCEMENTS
    • 6.1.5 INCREASING GOVERNMENT SUPPORT
  • 6.2 RESTRAINTS
    • 6.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT
    • 6.2.2 SIDE EFFECTS ASSOCIATED WITH DOWN SYNDROME TREATMENT THERAPIES
    • 6.2.3 HIGH COST OF DIAGNOSIS
  • 6.3 OPPORTUNITIES
    • 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
    • 6.3.2 INCREASING RESEARCH AND DEVELOPMENT
    • 6.3.3 PRESENCE OF PIPELINE THERAPIES
    • 6.3.4 PRESENCE OF REIMBURSEMENT
  • 6.4 CHALLENGES
    • 6.4.1 LACK OF SKILLED PROFFESSIONALS
    • 6.4.2 LONG PROCESS FOR PRODUCT LAUNCH
    • 6.4.3 TRANSFER OF COVID-19 INFECTIONS BY DIAGNOSTIC METHODS

7 IMPACT OF COVID-19 ON GLOBAL DOWN SYNDROME MARKET

  • 7.1 PRICE IMPACT
  • 7.2 IMPACT ON SUPPLY CHAIN
  • 7.3 IMPACT ON DEMAND
  • 7.4 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 7.5 CONCLUSION

8 GLOBAL DOWN SYNDROME MARKET, BY DISEASE TYPE

  • 8.1 OVERVIEW
  • 8.2 TRISOMY 21
  • 8.3 TRANSLOCATION DOWN SYNDROME
  • 8.4 MOSAIC DOWN SYNDROME

9 GLOBAL DOWN SYNDROME MARKET, BY TREATMENT

  • 9.1 OVERVIEW
  • 9.2 DIAGNOSIS
    • 9.2.1 SCREENING TESTS
      • 9.2.1.1 First Trimester
        • 9.2.1.1.1 Blood Test
        • 9.2.1.1.2 Nuchal Translucency Testing
      • 9.2.1.2 Integrated Screening Test
        • 9.2.1.2.1 First Trimester
        • 9.2.1.2.2 Second Trimester
      • 9.2.1.3 The Triple Screen or Quadraple Screen Test
      • 9.2.1.4 Ultrasound
      • 9.2.1.5 Cell Free DNA
    • 9.2.2 DIAGNOSTIC TESTS
      • 9.2.2.1 Chronic Villus Sampling
      • 9.2.2.2 Amniocentesis
      • 9.2.2.3 Precutaneous Umbical Cord Sampling
  • 9.3 THERAPY
    • 9.3.1 EARLY INTERVENTION THERAPY
      • 9.3.1.1 Speech-Language Therapy
      • 9.3.1.2 Physical Therapy
      • 9.3.1.3 Occupational Therapy
      • 9.3.1.4 Others
    • 9.3.2 ASSISTIVE TECHNOLOGY
      • 9.3.2.1 Hearing Aids
      • 9.3.2.2 Glasses
      • 9.3.2.3 Others
    • 9.3.3 SURGERY
      • 9.3.3.1 Atrioventricular Septal Defect (AVSD)
      • 9.3.3.2 Duodenal Atresia
      • 9.3.3.3 Others
    • 9.3.4 OTHERS

10 GLOBAL DOWN SYNDROME MARKET, BY END USER

  • 10.1 OVERVIEW
  • 10.2 HOSPITAL
  • 10.3 CLINICS
  • 10.4 HOMECARE SETTING
  • 10.5 OTHERS

11 GLOBAL DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL

  • 11.1 OVERVIEW
  • 11.2 DIRECT TENDER
  • 11.3 RETAIL SALES
  • 11.4 OTHERS

12 GLOBAL DOWN SYNDROME MARKET, BY GEOGRAPHY

  • 12.1 OVERVIEW
  • 12.2 NORTH AMERICA
    • 12.2.1 U.S.
    • 12.2.2 CANADA
    • 12.2.3 MEXICO
  • 12.3 EUROPE
    • 12.3.1 GERMANY
    • 12.3.2 U.K.
    • 12.3.3 FRANCE
    • 12.3.4 ITALY
    • 12.3.5 SPAIN
    • 12.3.6 RUSSIA
    • 12.3.7 POLAND
    • 12.3.8 SWITZERLAND
    • 12.3.9 NETHERLANDS
    • 12.3.10 HUNGARY
    • 12.3.11 AUSTRIA
    • 12.3.12 NORWAY
    • 12.3.13 IRELAND
    • 12.3.14 TURKEY
    • 12.3.15 LITHUANIA
    • 12.3.16 REST OF EUROPE
  • 12.4 ASIA-PACIFIC
    • 12.4.1 CHINA
    • 12.4.2 JAPAN
    • 12.4.3 AUSTRALIA
    • 12.4.4 SOUTH KOREA
    • 12.4.5 INDIA
    • 12.4.6 SINGAPORE
    • 12.4.7 THAILAND
    • 12.4.8 MALAYSIA
    • 12.4.9 INDONESIA
    • 12.4.10 PHILIPPINES
    • 12.4.11 VIETNAM
    • 12.4.12 REST OF ASIA-PACIFIC
  • 12.5 SOUTH AMERICA
    • 12.5.1 BRAZIL
    • 12.5.2 ARGENTINA
    • 12.5.3 PERU
    • 12.5.4 REST OF SOUTH AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 SOUTH AFRICA
    • 12.6.2 SAUDI ARABIA
    • 12.6.3 UAE
    • 12.6.4 ISRAEL
    • 12.6.5 KUWAIT
    • 12.6.6 EGYPT
    • 12.6.7 REST OF MIDDLE EAST & AFRICA

13 GLOBAL DOWN SYNDROME MARKET: COMPANY LANDSCAPE

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

14 COMPANY PROFILE

  • 14.1 F. HOFFMANN-LA ROCHE LTD
    • 14.1.1 COMPANY SNAPSHOT
    • 14.1.2 REVENUE ANALYSIS
    • 14.1.3 COMPANY ANALYSIS
    • 14.1.4 PRODUCT PORTFOLIO
    • 14.1.5 RECENT DEVELOPMENTS
  • 14.2 PERKINELMER INC.
    • 14.2.1 COMPANY SNAPSHOT
    • 14.2.2 REVENUE ANALYSIS
    • 14.2.3 COMPANY ANALYSIS
    • 14.2.4 PRODUCT PORTFOLIO
    • 14.2.5 RECENT DEVELOPMENTS
  • 14.3 ILLUMINA, INC.
    • 14.3.1 COMPANY SNAPSHOT
    • 14.3.2 REVENUE ANALYSIS
    • 14.3.3 COMPANY ANALYSIS
    • 14.3.4 PRODUCT PORTFOLIO
    • 14.3.5 RECENT DEVELOPMENTS
  • 14.4 THERMO FISHER SCIENTIFIC INC
    • 14.4.1 COMPANY SNAPSHOT
    • 14.4.2 REVENUE ANALYSIS
    • 14.4.3 COMPANY ANALYSIS
    • 14.4.4 PRODUCT PORTFOLIO
    • 14.4.5 RECENT DEVELOPMENTS
  • 14.5 MYRIAD GENETICS, INC.
    • 14.5.1 COMPANY SNAPSHOT
    • 14.5.2 REVENUE ANALYSIS
    • 14.5.3 COMPANY ANALYSIS
    • 14.5.4 PRODUCT PORTFOLIO
    • 14.5.5 RECENT DEVELOPMENTS
  • 14.6 ABBOTT
    • 14.6.1 COMPANY SNAPSHOT
    • 14.6.2 REVENUE ANALYSIS
    • 14.6.3 PRODUCT PORTFOLIO
    • 14.6.4 RECENT DEVELOPMENTS
  • 14.7 ABNOVA CORPORATION
    • 14.7.1 COMPANY SNAPSHOT
    • 14.7.2 PRODUCT PORTFOLIO
    • 14.7.3 RECENT DEVELOPMENTS
  • 14.8 ASDCLINIC.CO.UK
    • 14.8.1 COMPANY SNAPSHOT
    • 14.8.2 SERVICE PORTFOLIO
    • 14.8.3 RECENT DEVELOPMENT
  • 14.9 ATILABIOSYSTEMS
    • 14.9.1 COMPANY SNAPSHOT
    • 14.9.2 PRODUCT PORTFOLIO
    • 14.9.3 RECENT DEVELOPMENT
  • 14.10 BOSTON CHILDREN'S HOSPITAL
    • 14.10.1 COMPANY SNAPSHOT
    • 14.10.2 SERVICE PORTFOLIO
    • 14.10.3 RECENT DEVELOPMENTS
  • 14.11 BOYS TOWN NATIONAL RESEARCH HOSPITAL
    • 14.11.1 COMPANY SNAPSHOT
    • 14.11.2 SERVICE PORTFOLIO
    • 14.11.3 RECENT DEVELOPMENTS
  • 14.12 CHILDREN'S HOSPITAL COLORADO
    • 14.12.1 COMPANY SNAPSHOT
    • 14.12.2 SERVICE PORTFOLIO
    • 14.12.3 RECENT DEVELOPMENTS
  • 14.13 DEMEDITEC DIAGNOSTICS GMBH
    • 14.13.1 COMPANY SNAPSHOT
    • 14.13.2 PRODUCT PORTFOLIO
    • 14.13.3 RECENT DEVELOPMENT
  • 14.14 DOWN SYNDROME CORK
    • 14.14.1 COMPANY SNAPSHOT
    • 14.14.2 SERVICE PORTFOLIO
    • 14.14.3 RECENT DEVELOPMENTS
  • 14.15 MAYO CLINIC HEALTH SYSTEM
    • 14.15.1 COMPANY SNAPSHOT
    • 14.15.2 SERVICE PORTFOLIO
    • 14.15.3 RECENT DEVELOPMENTS
  • 14.16 NATERA, INC.
    • 14.16.1 COMPANY SNAPSHOT
    • 14.16.2 REVENUE ANALYSIS
    • 14.16.3 PRODUCT PORTFOLIO
    • 14.16.4 RECENT DEVELOPMENTS
  • 14.17 NEXT BIOSCIENCES
    • 14.17.1 COMPANY SNAPSHOT
    • 14.17.2 PRODUCT PORTFOLIO
    • 14.17.3 RECENT DEVELOPMENTS
  • 14.18 NOVUS BIOLOGICALS (A SUBSIDIARY OF BIO-TECHNE)
    • 14.18.1 COMPANY SNAPSHOT
    • 14.18.2 REVENUE ANALYSIS
    • 14.18.3 PRODUCT PORTFOLIO
    • 14.18.4 RECENT DEVELOPMENT
  • 14.19 KID SENSE CHILD DEVELOPMENT CORPORATION PTY LTD
    • 14.19.1 COMPANY SNAPSHOT
    • 14.19.2 SERVICE PORTFOLIO
    • 14.19.3 RECENT DEVELOPMENT
  • 14.20 PHYSIO.CO.UK.
    • 14.20.1 COMPANY SNAPSHOT
    • 14.20.2 SERVICE PORTFOLIO
    • 14.20.3 RECENT DEVELOPMENT
  • 14.21 SYMBOL
    • 14.21.1 COMPANY SNAPSHOT
    • 14.21.2 SERVICE PORTFOLIO
    • 14.21.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 GLOBAL DOWN SYNDROME MARKET: SEGMENTATION 47
  • FIGURE 2 GLOBAL DOWN SYNDROME MARKET : DATA TRIANGULATION 50
  • FIGURE 3 GLOBAL DOWN SYNDROME MARKET: DROC ANALYSIS 51
  • FIGURE 4 GLOBAL DOWN SYNDROME MARKET: GLOBAL VS. REGIONAL MARKET ANALYSIS 52
  • FIGURE 5 GLOBAL DOWN SYNDROME MARKET: COMPANY RESEARCH ANALYSIS 52
  • FIGURE 6 GLOBAL DOWN SYNDROME MARKET: MULTIVARIATE MODELLING 53
  • FIGURE 7 GLOBAL DOWN SYNDROME MARKET: INTERVIEW DEMOGRAPHICS 54
  • FIGURE 8 GLOBAL DOWN SYNDROME MARKET: DBMR MARKET POSITION GRID 55
  • FIGURE 9 GLOBAL DOWN SYNDROME MARKET: MARKET END USER COVERAGE GRID 56
  • FIGURE 10 GLOBAL DOWN SYNDROME MARKET: VENDOR SHARE ANALYSIS 57
  • FIGURE 11 GLOBAL DOWN SYNDROME MARKET: SEGMENTATION 61
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL DOWN SYNDROME MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028 62
  • FIGURE 13 INCREASING PREVALENCE OF DOWN SYNDROME AND OTHER RELATED DISORDERS AND RISING DEMAND FOR EFFECTIVE THERAPIES IS DRIVING THE GLOBAL DOWN SYNDROME MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 63
  • FIGURE 14 TRISOMY 21 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DOWN SYNDROME MARKET IN 2021 & 2028 63
  • FIGURE 15 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR DOWN SYNDROME MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028 64
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL DOWN SYNDROME MARKET 74
  • FIGURE 17 GLOBAL DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020 94
  • FIGURE 18 GLOBAL DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION) 95
  • FIGURE 19 GLOBAL DOWN SYNDROME MARKET: BY DISEASE TYPE, CAGR (2020-2028) 95
  • FIGURE 20 GLOBAL DOWN SYNDROME MARKET: BY DISEASE TYPE, LIFELINE CURVE 96
  • FIGURE 1 GLOBAL DOWN SYNDROME MARKET: BY TREATMENT, 2020 101
  • FIGURE 2 GLOBAL DOWN SYNDROME MARKET: BY TREATMENT, 2020-2028 (USD MILLION). 102
  • FIGURE 3 GLOBAL DOWN SYNDROME MARKET: BY TREATMENT, CAGR (2020-2028) 102
  • FIGURE 4 GLOBAL DOWN SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE 103
  • FIGURE 5 GLOBAL DOWN SYNDROME MARKET: BY END USER, 2020 114
  • FIGURE 6 GLOBAL DOWN SYNDROME MARKET: BY END USER, 2020-2028 (USD MILLION) 115
  • FIGURE 7 GLOBAL DOWN SYNDROME MARKET: BY END USER, CAGR (2020-2028) 115
  • FIGURE 8 GLOBAL DOWN SYNDROME MARKET: BY END USER, LIFELINE CURVE 116
  • FIGURE 9 GLOBAL DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020 122
  • FIGURE 10 GLOBAL DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION) 123
  • FIGURE 11 GLOBAL DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028) 123
  • FIGURE 12 GLOBAL DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 124
  • FIGURE 13 GLOBAL DOWN SYNDROME MARKET: SNAPSHOT (2020) 129
  • FIGURE 14 GLOBAL DOWN SYNDROME MARKET: BY REGION (2020) 130
  • FIGURE 15 GLOBAL DOWN SYNDROME MARKET: BY REGION (2021 & 2028) 130
  • FIGURE 16 GLOBAL DOWN SYNDROME MARKET: BY REGION (2020 & 2028) 131
  • FIGURE 17 GLOBAL DOWN SYNDROME MARKET: BY TREATMENT (2021-2028) 131
  • FIGURE 18 NORTH AMERICA DOWN SYNDROME MARKET: SNAPSHOT (2020) 133
  • FIGURE 19 NORTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2020) 134
  • FIGURE 20 NORTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028) 134
  • FIGURE 21 NORTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028) 135
  • FIGURE 22 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028) 135
  • FIGURE 23 EUROPE DOWN SYNDROME MARKET: SNAPSHOT (2020) 151
  • FIGURE 24 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2020) 152
  • FIGURE 25 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028) 152
  • FIGURE 26 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028) 153
  • FIGURE 27 EUROPE DOWN SYNDROME MARKET: BY TREATMENT (2021-2028) 153
  • FIGURE 28 ASIA-PACIFIC DOWN SYNDROME MARKET: SNAPSHOT (2020) 218
  • FIGURE 29 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2020) 219
  • FIGURE 30 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028) 219
  • FIGURE 31 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2021 - 2028) 220
  • FIGURE 32 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT (2021 & 2028) 220
  • FIGURE 33 SOUTH AMERICA DOWN SYNDROME MARKET: SNAPSHOT (2020) 270
  • FIGURE 34 SOUTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2020) 271
  • FIGURE 35 SOUTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028) 271
  • FIGURE 36 SOUTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028) 272
  • FIGURE 37 SOUTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028) 272
  • FIGURE 38 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: SNAPSHOT (2020) 290
  • FIGURE 39 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2020) 291
  • FIGURE 40 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028) 291
  • FIGURE 41 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028) 292
  • FIGURE 42 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028) 292
  • FIGURE 43 GLOBAL DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%) 323
  • FIGURE 44 NORTH AMERICA DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%) 324
  • FIGURE 45 EUROPE DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%) 325
  • FIGURE 46 ASIA-PACIFIC DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%) 326
Back to Top